Recently, bempegaldesleukin (BEMPEG), a cytokine prodrug of pegylated interleukin-2, emerged as a new potential treatment for advanced melanoma when combined with the immune checkpoint inhibitor nivolumab [31]. Here, IL2 is linked to melanoma.